Merck Join Forces with LaNova Medicines to Advance LM-299 for Advanced Solid Tumors
Shots:
- Merck and LaNova Medicines have collaborated to develop the latter’s LM-299 targeting advanced solid tumors
- As per the agreement, Merck gets exclusive worldwide rights for the development, manufacturing & commercialization of LM-299 in exchange of $588M upfront plus up to $2.7B milestones related to technology transfer, development, regulatory approval & commercialization, with the closing anticipated in Q4’24
- LM-299 (under P-I study across China) is a bispecific antibody targeting PD-1 & VEGF to inhibit immune checkpoints & angiogenesis. Its unique structure combines an anti-VEGF antibody with two anti-PD-1 single-domain antibodies
Ref: Merck | Image: LaNova & Merck
Related News:- LaNova Medicines Reports the Commencement of P-I Study Evaluating LM-299 for Solid Tumors and Completes Series C1 Financing Round
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
